article thumbnail

AAFP Represents Members During 2025 Legislative Session

Alabama Academy of Family Physicians

What Happened: The Senate Committee on Finance and Taxation Education did not meet to discuss the bill. Sponsored by Representative David Faulkner, the bill aims to provide more affordable health coverage options for farmers and self-employed agricultural workers who lack access to employer-sponsored plans.

Insurance 130
article thumbnail

MN Legislative Session 2025: Updates on Health Care Bills

Minnesota Academy of Family Physicians

As we move into the tenth week of the legislative session, Minnesota Academy of Family Physicians (MAFP) lobbyist Megan Verdeja breaks down what’s happening at the Minnesota State Capitol and provides an update on health care bills. HOUSE COMMERCE FINANCE AND POLICY COMMITTEE H.F. Read a summary of S.F. Read a summary of H.F.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ep. 68: Hidden risks of prescribing GLP-1 drugs with Ericka L. Adler, J.D., of Roetzel & Andress

Physician's Practice

68: Hidden risks of prescribing GLP-1 drugs with Ericka L. **Financial Relationships with Pharmaceutical Companies (00:20:10)** Legal and ethical concerns for physicians with financial ties to GLP-1 drug manufacturers, including anti-kickback laws.

article thumbnail

CMS proposes to Withdraw Trump Era Most Favored Nation (MFN) Drug Pricing Rule

FDA Law Blog

Predictably, PhRMA, BIO, and numerous provider organizations took advantage of the procedural irregularity to challenge the rule on APA grounds in three separate lawsuits, and succeeded in obtaining injunctions blocking the rule from taking effect on January 1, 2021 (as we reported here and here ). 3 , the “Elijah E.

Finance 52
article thumbnail

Drug Pricing Reform Gathers Steam (Part 1): White House Drug Pricing Plan Offers Laundry List of Existing Democrat Priorities

FDA Law Blog

A final OIG rule to change the structure of manufacturer rebates to Medicare Part D and Medicaid Managed Care plans and their PBMs is enmeshed in litigation and is likely to be at least postponed until 2026 (see our post ), and perhaps prevented from implementation altogether, by Congressional mandate.